DK3461891T3 - Nedstrømsbehandling af en alkalisk phosphatase - Google Patents
Nedstrømsbehandling af en alkalisk phosphatase Download PDFInfo
- Publication number
- DK3461891T3 DK3461891T3 DK18190484.8T DK18190484T DK3461891T3 DK 3461891 T3 DK3461891 T3 DK 3461891T3 DK 18190484 T DK18190484 T DK 18190484T DK 3461891 T3 DK3461891 T3 DK 3461891T3
- Authority
- DK
- Denmark
- Prior art keywords
- downtower
- treatment
- alkaline phosphatase
- phosphatase
- alkaline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03001—Alkaline phosphatase (3.1.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14152542 | 2014-01-24 | ||
EP15703640.1A EP3097188B1 (en) | 2014-01-24 | 2015-01-26 | Downstream processing of an alkaline phosphatase |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3461891T3 true DK3461891T3 (da) | 2020-08-10 |
Family
ID=49989634
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18190484.8T DK3461891T3 (da) | 2014-01-24 | 2015-01-26 | Nedstrømsbehandling af en alkalisk phosphatase |
DK15703640.1T DK3097188T3 (da) | 2014-01-24 | 2015-01-26 | Nedstrømsforarbejdning af en alkalisk phosphatase |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15703640.1T DK3097188T3 (da) | 2014-01-24 | 2015-01-26 | Nedstrømsforarbejdning af en alkalisk phosphatase |
Country Status (12)
Country | Link |
---|---|
US (2) | US10570380B2 (da) |
EP (2) | EP3097188B1 (da) |
JP (3) | JP6713147B2 (da) |
CN (3) | CN106459143A (da) |
CA (1) | CA2936829A1 (da) |
DK (2) | DK3461891T3 (da) |
ES (2) | ES2810813T3 (da) |
HU (2) | HUE040230T2 (da) |
PL (2) | PL3097188T3 (da) |
PT (1) | PT3461891T (da) |
SI (2) | SI3097188T1 (da) |
WO (1) | WO2015112015A1 (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3404102B1 (en) | 2004-04-21 | 2021-08-11 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
DK3097189T3 (da) | 2014-01-24 | 2018-09-03 | Am Pharma Bv | Kimæriske alkalisk phosphatase-lignende proteiner |
US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
AU2015357551B2 (en) | 2014-12-05 | 2021-02-25 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
CA2973883A1 (en) | 2015-01-28 | 2016-08-04 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
EP3337894A1 (en) | 2015-08-17 | 2018-06-27 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
EP3355904A4 (en) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA |
EP3368062A4 (en) | 2015-10-30 | 2019-07-03 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
MX2018011833A (es) | 2016-04-01 | 2019-02-13 | Alexion Pharma Inc | Tratamiento para la debilidad muscular con fosfatasas alcalinas. |
WO2017214130A1 (en) * | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
CA3057502A1 (en) | 2017-03-31 | 2018-10-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (hpp) in adults and adolescents |
US11338020B2 (en) | 2018-01-09 | 2022-05-24 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
EP3773686B1 (en) | 2018-03-20 | 2023-06-07 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
EP3768302A4 (en) | 2018-03-20 | 2021-12-15 | Synthetic Biologics, Inc. | INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS |
JP2021519590A (ja) | 2018-03-30 | 2021-08-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 糖タンパク質の製造 |
CN114126715A (zh) | 2019-05-31 | 2022-03-01 | 罗根生物技术有限公司 | 组合物以及解除细菌内毒素毒性的方法 |
US20240052327A1 (en) * | 2020-10-23 | 2024-02-15 | Alexion Pharmaceuticals, Inc. | Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8328918D0 (en) * | 1983-10-28 | 1983-11-30 | Unilever Plc | Alkaline phosphatase |
ATE157702T1 (de) | 1990-02-07 | 1997-09-15 | Abbott Lab | Alkalische phosphatase mit verbesserter spezifischer aktivität zur verwendung in indikatorreagenzien |
CA2102294A1 (en) | 1992-03-10 | 1993-09-11 | Jose L. Millan | Recombinant calf intestinal alkaline phosphatase |
AU698101B2 (en) | 1993-06-01 | 1998-10-22 | Cortex Pharmaceuticals, Inc. | Alkaline and acid phosphatase inhibitors in treatment of neurological disorders |
WO1995005455A1 (en) | 1993-08-13 | 1995-02-23 | Rijksuniversiteit Te Groningen | Pharmaceutical composition comprising phosphatase or a derivative thereof |
AU690941B2 (en) | 1993-11-15 | 1998-05-07 | Celtrix Pharmaceuticals, Inc. | Method of treating renal disease by administering IGF-I and IGFBP-3 |
US20020055098A1 (en) | 1994-04-18 | 2002-05-09 | Joseph Szasz | Thermostable alkaline phosphatases |
JP3625503B2 (ja) * | 1994-11-11 | 2005-03-02 | 旭化成ファーマ株式会社 | 臨床検査用複合酵素含有組成物 |
EP0851772A1 (en) | 1995-06-06 | 1998-07-08 | Gensci Regeneration Laboratories, Inc. | Modified osteogenic materials |
FR2736065B1 (fr) | 1995-06-29 | 1997-09-19 | Commissariat Energie Atomique | Phosphatases alcalines bacteriennes modifiees et leurs applications. |
EP0770678B1 (en) * | 1995-10-27 | 2003-01-22 | Amersham Biosciences Corp. | Thermostable alkaline phosphatase of Rhodothermus marinus |
JP3488327B2 (ja) | 1995-12-21 | 2004-01-19 | よつ葉乳業株式会社 | 牛乳脂肪球膜含有画分の製造法 |
US20020114802A1 (en) | 1998-02-10 | 2002-08-22 | Tjellstrom Bo Arthur Einar | Oral immunoglobulin treatment for inflammatory bowel disease |
DE19819962A1 (de) | 1998-05-05 | 1999-11-11 | Roche Diagnostics Gmbh | Hochaktive alkalische Phosphatase |
AU764247B2 (en) | 1998-12-21 | 2003-08-14 | Pharmaaware Ip B.V. | Diagnosis of sepsis using the LPS-binding moiety of alkaline phosphatase |
JP2000350596A (ja) | 1999-06-11 | 2000-12-19 | Toyobo Co Ltd | 分泌性アルカリフォスファターゼの選択的活性測定方法 |
PT1132086E (pt) | 2000-01-31 | 2006-09-29 | Pfizer Prod Inc | Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica |
ATE367374T1 (de) | 2000-07-19 | 2007-08-15 | Mitsubishi Pharma Corp | Sulphonsäurederivate von hydroxamsäuren und deren verwendung in medizinischen produkten |
EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
DE10101793A1 (de) | 2001-01-17 | 2002-08-01 | Manfred Nilius | Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen |
WO2002057430A2 (en) | 2001-01-20 | 2002-07-25 | Cardion Ag | Pluripotent adult stem cells derived from regenerative tissue |
WO2002098433A1 (fr) | 2001-06-01 | 2002-12-12 | Ajinomoto Co., Inc. | Medicaments pour les maladies intestinales |
JP3507890B2 (ja) | 2001-06-07 | 2004-03-15 | 大阪大学長 | Shewanellasp.SIB1株由来の新規なアルカリフォスファターゼ |
US7157260B2 (en) | 2001-07-26 | 2007-01-02 | Japan Science & Technology Agency | Nicotianamine synthase and gene encoding the same |
JP4169966B2 (ja) | 2001-11-14 | 2008-10-22 | 株式会社ヤクルト本社 | 炎症性腸疾患予防治療剤 |
CN1425766A (zh) | 2001-12-19 | 2003-06-25 | 复旦大学 | 一种多肽——人含碱性磷酸酶活性位点的蛋白-9.24和编码这种多肽的多核苷酸 |
CA2503621A1 (en) | 2002-11-13 | 2004-05-27 | Genentech, Inc. | Methods and compositions for diagnosing dysplasia |
US7048914B2 (en) | 2002-12-12 | 2006-05-23 | Zoltan Laboratories | Placental alkaline phosphatase to control diabetes |
AU2003295264A1 (en) | 2002-12-23 | 2004-07-14 | Rijksuniversiteit Groningen | Modulation of the thioredoxin pathway |
WO2004083432A1 (en) | 2003-03-21 | 2004-09-30 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
JP4305071B2 (ja) | 2003-06-30 | 2009-07-29 | 株式会社ニコン | 信号補正方法 |
JP2005065564A (ja) | 2003-08-22 | 2005-03-17 | Hiroshi Ueda | センサー蛋白質 |
US20110142817A1 (en) | 2004-02-04 | 2011-06-16 | Pharmaaware Sepsis B.V. | Means and method for treating and/or preventing necrotizing enterocolitis |
ES2624905T3 (es) | 2004-02-04 | 2017-07-18 | Am-Pharma B.V. | Uso de fosfatasa alcalina para la desintoxicación de LPS |
EP1856291A4 (en) | 2005-03-04 | 2009-04-01 | Verenium Corp | NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME |
US20070059300A1 (en) | 2005-09-12 | 2007-03-15 | Zoltan Laboratories Llc | Compounds and compositions to control abnormal cell growth |
EP1965830B1 (en) | 2005-12-28 | 2014-05-14 | Zoltan Laboratories Llc | Use of alkaline phosphatase to maintain healthy tissue mass in mammals |
US20070280922A1 (en) | 2006-06-06 | 2007-12-06 | Zoltan Kiss Consulting | Combinations of human proteins to enhance viability of stem cells and progenitor cells |
US7718170B2 (en) | 2006-08-21 | 2010-05-18 | Essential Skincare, Llc | Alkaline phosphatase compositions to reduce skin cancer |
EP1952823A1 (en) | 2007-01-30 | 2008-08-06 | AM-Pharma B.V. | The use of alkaline phosphatase in the treatment of reduced renal function |
WO2008104199A1 (en) | 2007-03-01 | 2008-09-04 | Gelato Corporation N.V. | Use of ecto-phosphatases for the treatment of (acute) myocardial infarction |
EP1985697A1 (en) * | 2007-04-27 | 2008-10-29 | AM-Pharma B.V. | Modified phosphatases |
EP2030980A1 (en) | 2007-08-28 | 2009-03-04 | AM-Pharma B.V. | Mutants of lactoferrin |
CA2716400C (en) | 2008-02-29 | 2017-05-09 | Alloksys Life Sciences B.V. | Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases |
JP2011521916A (ja) | 2008-05-19 | 2011-07-28 | バーナム インスティテュート フォー メディカル リサーチ | 腸アルカリホスファターゼモジュレーターおよびそれの使用 |
AU2009285725A1 (en) | 2008-08-29 | 2010-03-04 | The General Hospital Corporation | Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase |
KR101951446B1 (ko) | 2010-03-30 | 2019-02-22 | 옥타파마 아게 | 성장 인자 단백질을 정제하는 방법 |
JP2012196170A (ja) * | 2011-03-22 | 2012-10-18 | Sanyo Chem Ind Ltd | セルラーゼ組成物及びこのセルラーゼ組成物を含有する洗剤組成物 |
EP2717906B1 (en) * | 2011-06-08 | 2017-03-01 | AM-Pharma B.V. | The use of alkaline phosphatase for preserving renal function |
AU2012290379A1 (en) * | 2011-07-29 | 2014-02-06 | Eleven Biotherapeutics, Inc. | Purified proteins |
-
2015
- 2015-01-26 CN CN201580015952.3A patent/CN106459143A/zh active Pending
- 2015-01-26 HU HUE15703640A patent/HUE040230T2/hu unknown
- 2015-01-26 US US15/113,699 patent/US10570380B2/en active Active
- 2015-01-26 HU HUE18190484A patent/HUE051470T2/hu unknown
- 2015-01-26 DK DK18190484.8T patent/DK3461891T3/da active
- 2015-01-26 DK DK15703640.1T patent/DK3097188T3/da active
- 2015-01-26 PT PT181904848T patent/PT3461891T/pt unknown
- 2015-01-26 SI SI201530394T patent/SI3097188T1/sl unknown
- 2015-01-26 ES ES18190484T patent/ES2810813T3/es active Active
- 2015-01-26 CA CA2936829A patent/CA2936829A1/en active Pending
- 2015-01-26 EP EP15703640.1A patent/EP3097188B1/en active Active
- 2015-01-26 EP EP18190484.8A patent/EP3461891B1/en active Active
- 2015-01-26 ES ES15703640.1T patent/ES2688066T3/es active Active
- 2015-01-26 PL PL15703640T patent/PL3097188T3/pl unknown
- 2015-01-26 WO PCT/NL2015/050046 patent/WO2015112015A1/en active Application Filing
- 2015-01-26 SI SI201531291T patent/SI3461891T1/sl unknown
- 2015-01-26 CN CN202010985092.9A patent/CN112048491A/zh active Pending
- 2015-01-26 JP JP2016548122A patent/JP6713147B2/ja active Active
- 2015-01-26 PL PL18190484T patent/PL3461891T3/pl unknown
- 2015-01-26 CN CN202010985277.XA patent/CN112029753A/zh active Pending
-
2019
- 2019-09-04 US US16/560,608 patent/US20200063112A1/en not_active Abandoned
-
2020
- 2020-05-13 JP JP2020084763A patent/JP7039645B2/ja active Active
-
2021
- 2021-09-29 JP JP2021159692A patent/JP7449266B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6713147B2 (ja) | 2020-06-24 |
ES2810813T3 (es) | 2021-03-09 |
JP2017505613A (ja) | 2017-02-23 |
EP3461891B1 (en) | 2020-07-01 |
EP3461891A1 (en) | 2019-04-03 |
CN112029753A (zh) | 2020-12-04 |
WO2015112015A8 (en) | 2016-03-03 |
EP3097188B1 (en) | 2018-08-29 |
US20170009217A1 (en) | 2017-01-12 |
PT3461891T (pt) | 2020-07-30 |
HUE040230T2 (hu) | 2019-02-28 |
JP2020127427A (ja) | 2020-08-27 |
US20200063112A1 (en) | 2020-02-27 |
JP2022001061A (ja) | 2022-01-06 |
WO2015112015A1 (en) | 2015-07-30 |
EP3097188A1 (en) | 2016-11-30 |
SI3097188T1 (sl) | 2018-10-30 |
CN112048491A (zh) | 2020-12-08 |
US10570380B2 (en) | 2020-02-25 |
CN106459143A (zh) | 2017-02-22 |
HUE051470T2 (hu) | 2021-03-01 |
JP7039645B2 (ja) | 2022-03-22 |
DK3097188T3 (da) | 2018-10-08 |
SI3461891T1 (sl) | 2020-09-30 |
CA2936829A1 (en) | 2015-07-30 |
JP7449266B2 (ja) | 2024-03-13 |
PL3461891T3 (pl) | 2020-11-16 |
PL3097188T3 (pl) | 2018-11-30 |
ES2688066T3 (es) | 2018-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3461891T3 (da) | Nedstrømsbehandling af en alkalisk phosphatase | |
DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
DK3180331T3 (da) | Polymorfer af selinexor | |
DK2947898T3 (da) | Høreanordning | |
DK3307267T3 (da) | Behandling af multipel sklerose | |
DK3229995T3 (da) | Fremgangsmåde for fremstilling af et endestykke | |
DK3283210T3 (da) | Fremgangsmåde | |
DK3001700T3 (da) | Positioneret høresystem | |
DK3132009T3 (da) | Fremgangsmåde | |
DK3220891T3 (da) | Sublingual formulering af riluzol | |
DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
DK3201323T3 (da) | Modificering af bakteriofag | |
DK2897382T3 (da) | Forbedring af binaural kilde | |
DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
DK3418273T3 (da) | Derivater af flavagliner | |
DK3113773T3 (da) | Krystallinske former af grapiprant | |
DK3430004T3 (da) | Faststofformer af nilotinibsalte | |
FR3022129B1 (fr) | Baignoire de puericulture | |
DK3200783T3 (da) | Behandling af erytromelalgi |